Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD
Autore:
Lindahl, J; Kimby, E; Bjorkstrand, B; Christensson, B; Hellstrom-Lindberg, E;
Indirizzi:
Huddinge Univ Hosp, Karolinska Inst, Dept Med, Div Hematol, S-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden S-14186 tol, S-14186 Huddinge, Sweden Huddinge Univ Hosp, Karolinska Inst, Dept Pathol, S-14186 Huddinge, SwedenHuddinge Univ Hosp Huddinge Sweden S-14186 hol, S-14186 Huddinge, Sweden
Titolo Testata:
LEUKEMIA RESEARCH
fascicolo: 3, volume: 25, anno: 2001,
pagine: 267 - 270
SICI:
0145-2126(200103)25:3<267:HCAAAA>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; IMMUNOBLASTIC LYMPHADENOPATHY; CHROMOSOMAL-ABNORMALITIES; DYSPROTEINEMIA; LYMPHOMA;
Keywords:
angioimmunoblastic lymphadenopathy with dysproteinemia (AILD); autologous peripheral stemcell transplantation (APSCT); CD34+cells; hemolysis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Hellstrom-Lindberg, E Huddinge Univ Hosp, Karolinska Inst, Dept Med, Div Hematol, S-14186 Huddinge, Sweden Huddinge Univ Hosp Huddinge Sweden S-14186 Sweden
Citazione:
J. Lindahl et al., "High-dose chemotherapy and APSCT as a potential cure for relapsing hemolysing AILD", LEUK RES, 25(3), 2001, pp. 267-270

Abstract

Angioimmunoblastic lymphadenopathy with dysproteinemia (or dysgammaglobulinemia) (AILD) is a lymphoproliferative disorder with cytogenetic and molecular abnormalities characteristic of malignant T-cell lymphoma (angioimmunoblastic T-cell lymphoma - AITL). We report the clinical course of a 58-year-old male patient with unusually aggressive AILD, including severe hemolysisand Guillain-Barre syndrome, who entered complete remission after CHOP therapy, but had a full relapse after 2 months. At relapse, treatment with high-dose chemotherapy followed by autologous peripheral stem cell transplantation (APSCT) with CD34 selected cells was shown to be successful. The patient is alive and disease-free 3 years after diagnosis and 32 months after APSCT. Considering the poor prognosis of the majority of patients with AILD, intensive treatment followed by APSCT, may be a subject for further studies. (C) 2001 Elsevier Science Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 05:22:24